FOURIER & PCSK9 RNAi: Towards enhancing durability and efficacy of PCSK9 inhibitors

Authors

  • Mohamed Hassan Aswan Heart Centre, Aswan, Egypt

DOI:

https://doi.org/10.21542/gcsp.2017.13

Abstract

[first paragraph of article]

The 2003 discovery of proprotein convertase subtilisin–kexin type-9 (PCSK9) – a circulating protein targeting the low density lipoprotein (LDL) receptor for its degradation – paved the way for the development of several therapeutic approaches which inhibit the protein itself (by monoclonal antibodies) or its RNA (by RNA interference ‘‘RNAi’’). These drugs are a very promising and attractive therapy for high- risk cardiovascular (CV) patients, patients with statin intolerance, and those with familial hypercholesterolemia. 

Downloads

Published

2017-07-31

Issue

Vol. 2017 No. 2 (2017)

Section

Lessons from the trials

License

This is an open access article distributed under the terms of the Creative Commons Attribution license CC BY 4.0, which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.